Darren R Feldman

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors
    Darren R Feldman
    Darren R Feldman, Kristina Lim, Sujata Patil, Kaitlin M Woo, Maryann Carousso, Amanda Hughes, Joel Sheinfeld, Manjit Bains, Dean F Bajorin, George J Bosl, and Robert J Motzer, Memorial Sloan Kettering Cancer Center Darren R Feldman, Dean F Bajorin, George J Bosl, and Robert J Motzer, Weill Medical College of Cornell University, New York, NY and James Hu, Tanya B Dorff, Siamak Daneshmand, Charlene Ketchens, and David I Quinn, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA
    J Clin Oncol 34:2478-83. 2016
  2. pmc Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors
    Darren R Feldman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY Department of Medicine, Weill Cornell Medical College, New York, NY Electronic address
    Clin Genitourin Cancer 13:453-60. 2015
  3. doi request reprint Salvage high-dose chemotherapy for germ cell tumors
    Darren R Feldman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY Department of Medicine, Weill Medical College of Cornell University, New York, NY Electronic address
    Urol Oncol 33:355-62. 2015
  4. doi request reprint Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors
    Darren R Feldman
    Authors Affiliations Genitourinary Oncology Service, Department of Medicine Department of Medicine, Weill Medical College of Cornell University and
    Clin Cancer Res 20:3712-20. 2014
  5. doi request reprint Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older
    Darren R Feldman
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 119:2574-81. 2013
  6. doi request reprint A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors
    Darren R Feldman
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Invest New Drugs 31:1016-22. 2013
  7. ncbi request reprint Late cardiovascular toxicity following chemotherapy for germ cell tumors
    Darren R Feldman
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Natl Compr Canc Netw 10:537-44. 2012
  8. doi request reprint Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design
    Darren R Feldman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 118:981-6. 2012
  9. pmc TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis
    Darren R Feldman
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 28:1706-13. 2010
  10. doi request reprint Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors
    Darren R Feldman
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Invest New Drugs 28:523-8. 2010

Detail Information

Publications49

  1. doi request reprint Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors
    Darren R Feldman
    Darren R Feldman, Kristina Lim, Sujata Patil, Kaitlin M Woo, Maryann Carousso, Amanda Hughes, Joel Sheinfeld, Manjit Bains, Dean F Bajorin, George J Bosl, and Robert J Motzer, Memorial Sloan Kettering Cancer Center Darren R Feldman, Dean F Bajorin, George J Bosl, and Robert J Motzer, Weill Medical College of Cornell University, New York, NY and James Hu, Tanya B Dorff, Siamak Daneshmand, Charlene Ketchens, and David I Quinn, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA
    J Clin Oncol 34:2478-83. 2016
    ..We tested the efficacy of first-line TIP in patients with intermediate- or poor-risk disease...
  2. pmc Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors
    Darren R Feldman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY Department of Medicine, Weill Cornell Medical College, New York, NY Electronic address
    Clin Genitourin Cancer 13:453-60. 2015
    ....
  3. doi request reprint Salvage high-dose chemotherapy for germ cell tumors
    Darren R Feldman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY Department of Medicine, Weill Medical College of Cornell University, New York, NY Electronic address
    Urol Oncol 33:355-62. 2015
    ....
  4. doi request reprint Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors
    Darren R Feldman
    Authors Affiliations Genitourinary Oncology Service, Department of Medicine Department of Medicine, Weill Medical College of Cornell University and
    Clin Cancer Res 20:3712-20. 2014
    ..We sought to validate this finding by assessing for these mutations among patients with GCT at our center...
  5. doi request reprint Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older
    Darren R Feldman
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 119:2574-81. 2013
    ..Germ cell tumors (GCTs) primarily affect adolescent and young adult men. Detailed clinical and treatment characteristics in older men are lacking...
  6. doi request reprint A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors
    Darren R Feldman
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Invest New Drugs 31:1016-22. 2013
    ..Preclinical and phase 1 data suggested a possible role for MET in the pathophysiology of germ cell tumors (GCTs) and a potential clinical benefit from tivantinib in patients with these tumors...
  7. ncbi request reprint Late cardiovascular toxicity following chemotherapy for germ cell tumors
    Darren R Feldman
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Natl Compr Canc Netw 10:537-44. 2012
    ..In addition, recommendations are provided for the management of GCT survivors who received cisplatin-based chemotherapy and are therefore at risk for cardiovascular toxicity...
  8. doi request reprint Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design
    Darren R Feldman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 118:981-6. 2012
    ..The identification of novel active agents may be impaired by use of response as the primary endpoint in phase 2 trials. Improved endpoints could enhance the development of new effective agents...
  9. pmc TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis
    Darren R Feldman
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 28:1706-13. 2010
    ..We now report the efficacy of TI-CE with prognostic factors for disease-free survival (DFS) and overall survival (OS) in our full data set of 107 patients...
  10. doi request reprint Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors
    Darren R Feldman
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Invest New Drugs 28:523-8. 2010
    ..Correlation between sunitinib treatment and tumor marker changes on the 50 mg 4/2 schedule suggest some pathways targeted by sunitinib (ie, angiogenesis) may be important to GCT biology...
  11. doi request reprint Good-risk-advanced germ cell tumors: historical perspective and current standards of care
    Darren R Feldman
    Genitourinary Oncology Service Division of Solid Tumors, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    World J Urol 27:463-70. 2009
    ..The authors discuss the trials which led to the establishment of EPx4 and BEPx3 as today's treatment standards as well as the development of the IGCCCG prognostic model...
  12. pmc Treatment of stage I seminoma: is it time to change your practice?
    Darren R Feldman
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, USA
    J Hematol Oncol 1:22. 2008
    ..Carboplatin is not yet a standard of care. Surveillance-based strategies, including risk-adapted policies that limit RT to patients with the greatest likelihood of relapse remain prudent at this time...
  13. doi request reprint Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site
    Timothy A Masterson
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 79:1079-84. 2012
    ..To compare the survival outcomes of patients with advanced nonseminoma and extraretroperitoneal (ERP) disease observed for a clinical complete response (CCR) with those demonstrating a pathologic complete response (PCR)...
  14. doi request reprint Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer
    Timothy A Masterson
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Urology 79:156-9. 2012
    ..We reviewed our institutional experience in patients undergoing resection of extraretroperitoneal (ERP) residual masses after chemotherapy to assess its impact on cancer progression and survival...
  15. pmc Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma
    Ana M Molina
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Invest New Drugs 30:335-40. 2012
    ..6 months for the 8 papillary patients (95% CI, 1.4-7.1). The robust objective responses sunitinib had produced in clear cell RCC could not be demonstrated in this study comprised of patients with non-clear cell histologies...
  16. pmc Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma
    Ana M Molina
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 118:1868-76. 2012
    ..Everolimus, an oral mTOR inhibitor, and sunitinib, an oral tyrosine kinase inhibitor targeting VEGF, are standard agents in the management of metastatic RCC...
  17. doi request reprint Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors
    Ashwin Jathavedam
    Infectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Biol Blood Marrow Transplant 14:595-600. 2008
    ..In conclusion, serious morbidity from infection is uncommon among GCT patients receiving high-dose chemotherapy with ASCT. Isolation and aggressive antifungal and antiviral prophylaxis is not warranted in these patients...
  18. pmc Long-term response to sunitinib therapy for metastatic renal cell carcinoma
    Ana M Molina
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Genitourin Cancer 11:297-302. 2013
    ..The characteristics of patients who achieved long-term response (defined as patients achieving ongoing complete response [CR] or remaining progression free for > 18 months while receiving sunitinib) are reported...
  19. pmc Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease
    Ana M Molina
    Department of Medicine, Genitourinary Oncology Service, Weil Medical College of Cornell University, New York, NY, USA
    Am J Clin Oncol 34:454-9. 2011
    ..Sarcomatoid variant is a spindle cell phenotype of renal cell carcinoma (RCC), which is associated with a poor prognosis. We reviewed outcomes of systemic therapy for metastatic, sarcomatoid-variant RCC...
  20. ncbi request reprint Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors
    Darren R Feldman
    Genitourinary Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Invest New Drugs 25:487-90. 2007
    ..For patients who had previously received taxane therapy, ixabepilone was not efficacious in the treatment of cisplatin-refractory GCT...
  21. doi request reprint Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an update
    Amit Gupta
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Urology 77:655-9. 2011
    ..To examine histologic findings and clinical outcomes of patients who underwent neck dissection for residual neck masses...
  22. doi request reprint Medical treatment of advanced testicular cancer
    Darren R Feldman
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    JAMA 299:672-84. 2008
    ..Clinicians need to be familiar with the available treatment regimens for testicular cancer and their associated toxic effects...
  23. pmc Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma
    Darren R Feldman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 27:1432-9. 2009
    ..In this phase I study, the maximum-tolerated dose (MTD) and safety of sunitinib in combination with bevacizumab were examined in patients with advanced RCC...
  24. pmc Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors
    James E Korkola
    Cell Biology Program, Sloan Kettering Institute for Cancer Research, New York, USA
    J Clin Oncol 27:5240-7. 2009
    ..Currently, patients are risk-stratified on the basis of clinical presentation and serum tumor markers. The introduction of molecular markers could improve outcome prediction...
  25. pmc A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors
    Martin H Voss
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Hematol Oncol Clin North Am 25:557-76, viii -ix. 2011
    ..Clinical factors can help prognosticate patients, and recently an international effort developed a prognostic model for the second-line setting that can be universally applied in future studies...
  26. pmc A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
    Maria I Carlo
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Oncologist 21:787-8. 2016
    ..Because of toxicity and lack of efficacy, BEZ235 should not be further developed in the current formulation for patients with renal cell carcinoma...
  27. pmc Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach
    James E Korkola
    Cell Biology Program, Sloan Kettering Institute for Cancer Research, New York, New York, United States of America
    PLoS ONE 10:e0142846. 2015
    ..These genes may aid in the identification of the small subset of patients who are at high risk of poor outcome. ..
  28. doi request reprint Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasis
    Diogo A Bastos
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
    Clin Genitourin Cancer 13:59-66. 2015
    ..The role of targeted therapy in this setting is not well established. The primary objective was to assess overall survival (OS) and neurologic events in patients with brain metastasis treated with targeted agents...
  29. doi request reprint High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis
    Russell A Moore
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room H709, New York, NY 10065, USA
    J Clin Oncol 29:3466-73. 2011
    ....
  30. ncbi request reprint Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma
    Darren R Feldman
    Genitourinary Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Genitourin Cancer 6:25-30. 2008
    ..In this study, the efficacy and toxicity of pegylated IFN was assessed in patients with metastatic renal cell carcinoma (mRCC)...
  31. pmc Contemporary lymph node counts during primary retroperitoneal lymph node dissection
    R Houston Thompson
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Urology 77:368-72. 2011
    ..We report our contemporary single-surgeon experience with lymph node counts during primary RPLND for nonseminomatous germ cell tumors...
  32. pmc Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics
    Lois B Travis
    Affiliations of authors Rubin Center for Cancer Survivorship and Department of Radiation Oncology LBT and Department of Neurology DNH, University of Rochester Medical Center, Rochester, NY Department of Oncology, Oslo University Hospital, Radiumhospital, Oslo, Norway SDF Division of Preventive Medicine, Department of Medicine, Brigham and Women s Hospital, Boston, MA HDS Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA CJB Department of Chemical and Biomedical Engineering, University of South Florida, Tampa, FL RDF Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY DRF Department of Genitourinary Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX LCP Department of Radiation Oncology, Mayo Clinic, Rochester, MN RCM Department of Medicine, University of Pennsylvania, Philadelphia, PA DJV Department of Medical Oncology, Indiana University, Indianapolis, IN LHE Departments of Human Genetics NJC and Medicine MED, University of Chicago, Chicago, IL
    J Natl Cancer Inst 106:. 2014
    ....
  33. pmc Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors
    Roy Mano
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
    J Urol . 2016
    ..We characterized patients with fibrosis at post-chemotherapy retroperitoneal lymph node dissection and identified predictors of adverse outcomes in this group...
  34. pmc Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs
    Chung Han Lee
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
    Clin Genitourin Cancer 14:56-62. 2016
    ..Bevacizumab monotherapy resulted in prolonged disease control and few discontinuations for adverse events, including for patients who were heavily pretreated...
  35. doi request reprint Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors
    Yevgeniy Balagula
    Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
    Cancer 118:5078-83. 2012
    ..Inhibitors of mammalian target of rapamycin (mTOR), such as temsirolimus and everolimus, have been associated with a high rate of skin eruptions, but their clinical and histopathologic characteristics have not been explored...
  36. pmc High-dose chemotherapy and stem cell transplantation for advanced testicular cancer
    Martin H Voss
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Expert Rev Anticancer Ther 11:1091-103. 2011
    ..Patients that relapse after HDCT are usually considered incurable, and additional therapy is provided with palliative intent...
  37. ncbi request reprint Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma
    Martin H Voss
    Martin H Voss, Ying Bei Chen, Kaitlin M Woo, Joshua L Chaim, Devyn T Coskey, Almedina Redzematovic, Patricia Wang, William Lee, S Duygu Selcuklu, Chung Han Lee, Michael F Berger, Satish K Tickoo, Victor E Reuter, Sujata Pati, James J Hsieh, Robert J Motzer, and Darren R Feldman, Memorial Sloan Kettering Cancer Center and Ana M Molina, Weill Cornell Medical College, New York, NY
    J Clin Oncol . 2016
    ..We evaluated the efficacy of everolimus plus bevacizumab in patients with metastatic ncRCC...
  38. pmc Development of a risk stratification system to guide treatment for female germ cell tumors
    Jane L Meisel
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States
    Gynecol Oncol 138:566-72. 2015
    ..Due to their rarity, little is known about prognostic factors in female germ cell tumors (GCTs) or outcomes following systemic therapy. Management is largely based on studies of male GCT and epithelial ovarian cancer...
  39. pmc Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group
    Darren R Feldman
    Darren R Feldman, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY Anja Lorch, University Hospital Dusseldorf, Düsseldorf Carsten Bokemeyer, University Hospital Eppendorf, Hamburg, Germany Andrew Kramar, Centre Oscar Lambret, Lille Aude Flechon and Helen Boyle, Centre Leon Berard, Lyon, France Costantine Albany and Lawrence H Einhorn, Indiana University, Bloomington, IN Patrizia Giannatempo and Andrea Necchi, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milano Teodoro Sava, Azienda Ospedaliera Universitaria Integrata di Verona, Verona Ugo De Giorgi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituto di Ricovero e Cura a Carattere Scientifico, Meldola, Italy Peter Chung, Princess Margaret Cancer Centre, University of Toronto, Toronto Eric William Winquist, London Health Sciences Center, London, Ontario, Canada Robert A Huddart, Royal Marsden Hospital Thomas Powles, St Bartholomew s Hospital, London, United Kingdom Alexey Tryakin, Blokhin s Russian Cancer Research Center, Moscow,
    J Clin Oncol 34:345-51. 2016
    ..To define characteristics, treatment response, and outcomes of men with brain metastases (BM) from germ cell tumors (GCT)...
  40. ncbi request reprint Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach
    Clair J Beard
    From Department of Radiation Oncology, Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, Massachusetts Division of Medical Oncology, Moffitt Cancer Center, Tampa, Florida Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Division of Medical Oncology, Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, Massachusetts Department of Hematology Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania Division of Oncology, Stanford University Medical Center, Palo Alto, California Division of Hematology Oncology, The University of California, San Francisco, California Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
    J Natl Compr Canc Netw 13:811-22. 2015
    ..This article provides a review of the available evidence, integrated with expert medical judgment, in the area of testicular cancer follow-up. ..
  41. doi request reprint Late Relapse of Testicular Germ Cell Tumors
    Matthew J O'Shaughnessy
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 353 East 68th Street, New York, NY 10065, USA
    Urol Clin North Am 42:359-68. 2015
    ....
  42. pmc Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition
    Francesca Cavallo
    Department of Biomedicine and Prevention, Section of Anatomy, University of Rome Tor Vergata, Rome, Italy
    PLoS ONE 7:e51563. 2012
    ....
  43. doi request reprint The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis
    Yevgeniy Balagula
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion Suite 228, 160 East 53rd Street, New York, NY 10022, USA
    Invest New Drugs 30:1773-81. 2012
    ..1-6.2, p < 0.001). Despite sharing the same spectrum of target receptors with sorafenib and sunitinib, pazopanib is associated with an unexpectedly low risk of HFSR. Further investigations are needed to elucidate HFSR pathogenesis...
  44. pmc Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer
    Robert D Frisina
    Robert D Frisina, University of South Florida, Tampa, FL Heather E Wheeler, Loyola University Chicago M Eileen Dolan, University of Chicago, Chicago, IL Sophie D Fossa, Oslo University Hospital, Radiumhospital, Oslo, Norway Sarah L Kerns, Chunkit Fung, and Eileen M Johnson, J P Wilmot Cancer Institute, University of Rochester Medical Center, Rochester Darren R Feldman and Amy Budnick, Memorial Sloan Kettering Cancer Center, New York, NY Howard D Sesso, Brigham and Women s Hospital Clair J Beard, Dana Farber Cancer Institute, Boston, MA Patrick O Monahan, Shirin Ardeshir Rouhani Fard, Lawrence H Einhorn, and Lois B Travis, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN Robert Hamilton, Princess Margaret Cancer Centre, Toronto, ON David J Vaughn, University of Pennsylvania, Philadelphia, PA and Steven E Lipshultz, Children s Hospital of Michigan, Wayne State University School of Medicine, Detroit, MI
    J Clin Oncol 34:2712-20. 2016
    ..Cisplatin is widely used but highly ototoxic. Effects of cumulative cisplatin dose on hearing loss have not been comprehensively evaluated in survivors of adult-onset cancer...
  45. pmc Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial
    Darren R Feldman
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York USA
    J Cancer 2:374-7. 2011
    ..It is hoped that this large study will conclusively resolve the uncertainty which currently exists...
  46. doi request reprint Fertility preservation strategies for male patients with cancer
    Darren J Katz
    Male Sexual and Reproductive Medicine Program, Memorial Sloan Kettering Cancer Center, Urology Service, Department of Surgery, 1275 York Avenue, New York, NY 10065, USA
    Nat Rev Urol 10:463-72. 2013
    ..Before any of these techniques become clinically viable, a number of scientific, logistical and ethical issues will need to be resolved...
  47. doi request reprint Long-term mortality in patients with germ cell tumors: effect of primary cancer site on cause of death
    Shaheen R Alanee
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY Electronic address
    Urol Oncol 32:26.e9-15. 2014
    ..To examine the effect of extragonadal tumor site on the risk for cardiovascular, hematopoietic malignancies, and solid cancer-related causes of death...
  48. ncbi request reprint Novel targets and therapies for metastatic renal cell carcinoma
    Darren R Feldman
    Division of Medical Oncology and Hematology, Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Oncology (Williston Park) 20:1745-53; discussion 1756. 2006
    ..The ways in which these novel drugs are changing the standard of care for metastatic RCC and the future directions of RCC clinical trials are also discussed...
  49. pmc Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors
    Dana Rathkopf
    Genitourinary Oncology Service, Department of Medicine, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 15:7405-11. 2009
    ..Preclinical data indicate that flavopiridol enhances oxaliplatin- and fluorouracil (5FU)-induced apoptosis in a sequence-dependent manner...